Simon P Byrne1, Ronald M Rapee1, Rick Richardson2, Gin S Malhi3, Michael Jones1, Jennifer L Hudson1. 1. Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, New South Wales, Australia. 2. School of Psychology, University of New South Wales, Sydney, New South Wales, Australia. 3. CADE Clinic, Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: For exposure therapy to be successful, it is essential that fear extinction learning extends beyond the treatment setting. D-cycloserine (DCS) may facilitate treatment gains by increasing generalization of extinction learning, however, its effects have not been tested in children. We examined whether DCS enhanced generalization of fear extinction learning across different stimuli and contexts among children with specific phobias. METHODS: The study was a double-blind placebo-controlled randomized controlled trial among dog or spider phobic children aged 6-14. Participants ingested either 50 mg of DCS (n = 18) or placebo (n = 17) before receiving a single prolonged exposure session to their feared stimulus. Return of fear was examined 1 week later to a different stimulus (a different dog or spider), presented in both the original treatment context and an alternate context. Avoidance and fear were measured with Behavior Approach Tests (BATs), where the child was asked to increase proximity to the stimulus while reporting their fear level. RESULTS: There were no differences in BAT performance between groups during the exposure session or when a new stimulus was later presented in the treatment context. However, when the new stimulus was presented in a different context, relative to placebo, the DCS group showed less avoidance (P = .03) and less increase in fear (P = .04) with moderate effect sizes. CONCLUSIONS:DCS enabled children to better retain their fear extinction learning. This new learning generalized to different stimuli and contexts.
RCT Entities:
BACKGROUND: For exposure therapy to be successful, it is essential that fear extinction learning extends beyond the treatment setting. D-cycloserine (DCS) may facilitate treatment gains by increasing generalization of extinction learning, however, its effects have not been tested in children. We examined whether DCS enhanced generalization of fear extinction learning across different stimuli and contexts among children with specific phobias. METHODS: The study was a double-blind placebo-controlled randomized controlled trial among dog or spider phobic children aged 6-14. Participants ingested either 50 mg of DCS (n = 18) or placebo (n = 17) before receiving a single prolonged exposure session to their feared stimulus. Return of fear was examined 1 week later to a different stimulus (a different dog or spider), presented in both the original treatment context and an alternate context. Avoidance and fear were measured with Behavior Approach Tests (BATs), where the child was asked to increase proximity to the stimulus while reporting their fear level. RESULTS: There were no differences in BAT performance between groups during the exposure session or when a new stimulus was later presented in the treatment context. However, when the new stimulus was presented in a different context, relative to placebo, the DCS group showed less avoidance (P = .03) and less increase in fear (P = .04) with moderate effect sizes. CONCLUSIONS:DCS enabled children to better retain their fear extinction learning. This new learning generalized to different stimuli and contexts.
Authors: Joseph F McGuire; Scott P Orr; Joey K-Y Essoe; James T McCracken; Eric A Storch; John Piacentini Journal: Expert Rev Neurother Date: 2016-06-27 Impact factor: 4.618
Authors: Lindsey J Noble; Venkat B Meruva; Seth A Hays; Robert L Rennaker; Michael P Kilgard; Christa K McIntyre Journal: Brain Stimul Date: 2018-09-21 Impact factor: 8.955
Authors: Joseph F McGuire; Monica S Wu; John Piacentini; James T McCracken; Eric A Storch Journal: J Clin Psychiatry Date: 2017-02 Impact factor: 4.384
Authors: Lara J Farrell; Allison M Waters; Ella L Oar; Evelin Tiralongo; Vinay Garbharran; Clair Alston-Knox; Harry McConnell; Nigel Collings; Melanie Zimmer-Gembeck; Caroline L Donovan; Chris Testa; Eric A Storch; Thomas H Ollendick Journal: Brain Behav Date: 2018-05-01 Impact factor: 2.708